JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265092

Human RALA knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

RALA KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 2. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Western blot - Human RALA knockout HeLa cell line (AB265092)
  • WB

Lab

Western blot - Human RALA knockout HeLa cell line (AB265092)

Lanes 1-3 : Merged signal (red and green). Green - ab126627 observed at 25 kDa. Red - loading control ab7291 observed at 50 kDa.

ab126627 Anti-RALA antibody [EPR6468] was shown to specifically react with RALA in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab265092 (knockout cell lysate ab258165) was used. Wild-type and RALA knockout samples were subjected to SDS-PAGE. ab126627 and Anti-alpha Tubulin antibody [DM1A] - Loading Control (ab7291) were incubated overnight at 4° at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-RALA antibody [EPR6468] (<a href='/en-us/products/primary-antibodies/rala-antibody-epr6468-ab126627'>ab126627</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

RALA knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human RALA knockout HeLa cell line (ab265092)

Lane 3:

MCF7 cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/20000 dilution

Predicted band size: 24 kDa

Observed band size: 25 kDa

false

Sanger Sequencing - Human RALA knockout HeLa cell line (AB265092)
  • Sanger seq

Unknown

Sanger Sequencing - Human RALA knockout HeLa cell line (AB265092)

Homozygous : 1 bp deletion in exon 2.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 2

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265092-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265092 Human RALA knockout HeLa cell line", "number":"AB265092-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265092-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265092-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265092 Human RALA knockout HeLa cell line", "number":"AB265092-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265092-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265092-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265092 Human RALA knockout HeLa cell line", "number":"AB265092-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265092-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265092 Human RALA knockout HeLa cell line", "number":"AB265092-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
RALA
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

RALA also known as Ras-related protein Ral-A or RalA is a small GTPase involved in a variety of cellular processes. It has a molecular mass of approximately 23 kDa. RALA switches between inactive GDP-bound and active GTP-bound states facilitating the transduction of signals within the cell. This protein is found in a range of tissues with expression in the brain lung and kidney being notable. The ability of RALA to shuttle between membrane compartments highlights its mechanical versatility in cellular signaling.
Biological function summary

The interaction of RALA with effector proteins drives key processes like vesicle trafficking cytoskeletal dynamics and gene expression. RALA forms part of a signaling complex in its active state that mediates these functions. This protein is vital in the neurotransmitter release ensuring efficient communication between neurons. Additionally RALA impacts cell movement by influencing actin filament organization showing its role in cell motility.

Pathways

The engagement of RALA in Ral signaling and the phosphatidylinositol 3-kinase (PI3K) pathway showcases its importance. In Ral signaling RALA interacts closely with proteins like RalBP1 influencing endocytosis and exocytosis activities. In the PI3K pathway RALA helps regulate cell proliferation and survival showing interactions with proteins such as AKT1. These pathways highlight the integration of RALA into broad signal transduction networks important for cellular homeostasis.

The altered regulation of RALA links it to cancer and neuronal disorders. In cancer the dysregulation of RALA can drive tumorigenesis often acting alongside proteins like KRAS in promoting oncogenic signaling. In neuronal disorders improper functioning of RALA has been associated with synaptic dysfunctions potentially affecting proteins like Synapsin I which are important to synaptic vesicle trafficking. Understanding RALA's role in these contexts helps in developing targeted therapeutic strategies.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com